Skip to content

Glucose/Insulin Responses:Subjects With Type 2 Diabetes Consuming Diabetes-Specific vs Standard Nutritional Formulas

Randomized, Double Blind, Three Way Crossover Comparison of Glucose and Insulin Responses During a Meal Glucose Tolerance Test in Subjects With Type 2 Diabetes Consuming Disease-Specific Versus Standard Nutritional Formula

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00540488
Enrollment
54
Registered
2007-10-08
Start date
2002-08-31
Completion date
Unknown
Last updated
2007-10-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus Type 2

Brief summary

To measure and compare the glycemic and insulinemic responses of subjects consuming a standard and two diabetes-specific products.

Interventions

OTHERAdult enteral formula

Sponsors

Abbott Nutrition
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years

Inclusion criteria

* signed and dated informed consent * 18-75 years of age * history of type 2 diabetes * males and non-pregnant, non-lactating females

Exclusion criteria

* subject uses insulin for glucose control * significant cardiovascular event \<12 weeks prior to study entry * active malignancies * history of end stage renal disease * history of organ transplant * current hepatic disease * intervention for HIB * takes niacin * history of gastroparesis * active disease that may interfere with nutrient intake * allergy or intolerance to ingredients in the study products

Design outcomes

Primary

MeasureTime frame
Adjusted area under the curve (adj-AUC) of glucose response0-240 minutes

Secondary

MeasureTime frame
Adjusted peak for glucose and insulin response;peak time for glucose and insulin response; Adj-AUC for insulin response; change in glucose and insulin; subjective gastrointestinal tolerance0 - 240 minutes

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026